CME
37
-12
KLAC
52
-7
EOG
29
-7
IBM
41
-5
DE
35
-17
HBI
43
-6
BIIB
30
-6
EMN
45
-7
ETN
46
-9
AXP
50
-9
ILMN
17
-5
CMCSA
39
-7
HAL
30
-9
IRM
59
21
C
39
-5
BAX
32
-9
ADSK
44
-4
AKAM
26
-6
BMY
23
-10
GOOGL
34
-9
CME
37
-12
KLAC
52
-7
EOG
29
-7
IBM
41
-5
DE
35
-17
HBI
43
-6
BIIB
30
-6
EMN
45
-7
ETN
46
-9
AXP
50
-9
ILMN
17
-5
CMCSA
39
-7
HAL
30
-9
IRM
59
21
C
39
-5
BAX
32
-9
ADSK
44
-4
AKAM
26
-6
BMY
23
-10
GOOGL
34
-9
Financhill
Back

OptimizeRx Stock Predictions

Crowdfunding to IPO: Nasdaq's Next Breakout?

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
22

OPRX
OptimizeRx

Last Price:
$8.19
Seasonality Move:
41.18%

7 Day Trial

ALL ACCESS PASS

$ 7

Meet the founder that's revolutionizing smartphones

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.

OptimizeRx Stock Forecast

  • Over the next 52 weeks, OptimizeRx has on average historically risen by 72.7% based on the past 15 years of stock performance.
  • OptimizeRx has risen higher in 4 of those 15 years over the subsequent 52-week period, corresponding to a historical accuracy of 26.67%
  • Is OptimizeRx Stock Undervalued?
    The current OptimizeRx [OPRX] share price is $8.16. The Score for OPRX is 22, which is 56% below its historic median score of 50, and infers higher risk than normal.
  • OPRX is currently trading in the 20-30% percentile range relative to its historical Stock Score levels.

Will OptimizeRx Stock Go Up Next Year?

  • Over the next 52 weeks, OptimizeRx has on average historically risen by 72.7% based on the past 15 years of stock performance.

OptimizeRx Stock Rating

Sell
22
OptimizeRx (OPRX) is a Sell

Is OptimizeRx overpriced?

  • OptimizeRx has risen higher in 4 of those 15 years over the subsequent 52-week period, corresponding to a historical accuracy of 26.67%

OptimizeRx Stock Price History

Is OPRX stock going to rise?

  • Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and OPRX is experiencing buying pressure, which is a positive indicator for future bullish movement.

Stock Information

Stock Info

Exchange:
NASDAQ
Country:
United States
Industry:
Health Care Technology
Sector:
Health Care
Type:
stock
Website:
optimizerx.com

52-Week Data

52-Week High:
14.13
52-Week Low:
3.78

Prediction Charts

Market Cap:
150.9M
Price in USD:
8.16
Volume:
198.2K
Beta:
0.73

Technical Analysis

SMA50:
6.73
SMA100:
5.91
SMA200:
7.07
52-Wk Change:
-25.48%

Stock Predictions

  • Is OptimizeRx stock public?
    Yes, OptimizeRx is a publicly traded company.
  • What is the OptimizeRx stock quote today?
    The OptimizeRx stock price is 8.16 USD today.
  • How to buy OptimizeRx stock online?
    You can buy OptimizeRx shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

14-Day Historical Data

Date Opening Closing Minimum Maximum
Mar-24 8.76 9.00 9.04 8.51
Mar-25 9.10 9.47 9.84 8.91
Mar-26 9.41 8.74 9.41 8.71
Mar-27 8.75 8.74 9.30 8.69
Mar-28 8.73 8.64 8.91 8.34
Mar-31 8.59 8.66 8.94 8.26
Apr-1 8.65 8.18 8.71 7.95
Apr-2 8.08 8.33 8.41 7.86
Apr-3 7.76 7.88 8.15 7.68
Apr-4 7.48 7.75 7.78 7.07
Apr-7 7.26 7.88 8.10 6.88
Apr-8 8.26 7.44 8.26 6.80
Apr-9 7.39 8.29 8.32 7.15
Apr-10 8.07 8.16 8.25 7.60

OptimizeRx Earnings

OptimizeRx Earnings Report: Per Share OptimizeRx Earnings Q1 Q2 Q3 and Q4 last year and next year.

OptimizeRx Forecast Revenue Growth

OptimizeRx Stock Analysis: Historical quarterly revenues per share for OptimizeRx and historical quarterly revenue growth:

  • Analysts estimate an earnings increase this quarter of $0.06 per share, a decrease next quarter of $0.20 per share, an increase this year of $0.09 per share, and an increase next year of $0.19 per share.

* OptimizeRx stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.